TY - JOUR AU - Creutzfeldt, W. PY - 1996 DA - 1996// TI - Carcinoid tumors: development of our knowledge JO - World J Surg VL - 20 UR - https://doi.org/10.1007/s002689900020 DO - 10.1007/s002689900020 ID - Creutzfeldt1996 ER - TY - JOUR AU - Halperin, D. M. AU - Shen, C. AU - Dasari, A. PY - 2017 DA - 2017// TI - Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30110-9 DO - 10.1016/S1470-2045(17)30110-9 ID - Halperin2017 ER - TY - JOUR AU - Kulke, M. H. PY - 2016 DA - 2016// TI - Somatostatin analogues in neuroendocrine tumors JO - J Natl Compr Cancer Netw VL - 14 UR - https://doi.org/10.6004/jnccn.2016.0029 DO - 10.6004/jnccn.2016.0029 ID - Kulke2016 ER - TY - STD TI - US Food and Drug Administration. Sandostatin LAR Depot prescribing information. 2014. http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_lar.pdf. Accessed 10 July 2018. UR - http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_lar.pdf ID - ref4 ER - TY - STD TI - US Food and Drug Administration. Somatuline Depot prescribing information. 2007. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s011lbl.pdf. Accessed 10 July 2018. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s011lbl.pdf ID - ref5 ER - TY - STD TI - U.S. FDA approves new indication for Ipsen's Somatuline Depot (lanreotide) injection for the treatment of carcinoid syndrome. 2017. https://www.ipsen.com/websites/IPSENCOM-PROD/wp-content/uploads/2017/09/16000129/18-09-2017-Approval-Somatuline-US-carcinoid-syndrom-FINAL.pdf. Accessed 10 July 2018. UR - https://www.ipsen.com/websites/IPSENCOM-PROD/wp-content/uploads/2017/09/16000129/18-09-2017-Approval-Somatuline-US-carcinoid-syndrom-FINAL.pdf ID - ref6 ER - TY - JOUR AU - Beaumont, J. L. AU - Cella, D. AU - Phan, A. T. AU - Choi, S. AU - Liu, Z. AU - Yao, J. C. PY - 2012 DA - 2012// TI - Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population JO - Pancreas. VL - 41 UR - https://doi.org/10.1097/MPA.0b013e3182328045 DO - 10.1097/MPA.0b013e3182328045 ID - Beaumont2012 ER - TY - JOUR AU - Haugland, T. AU - Vatn, M. H. AU - Veenstra, M. AU - Wahl, A. K. AU - Natvig, G. K. PY - 2009 DA - 2009// TI - Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population JO - Qual Life Res VL - 18 UR - https://doi.org/10.1007/s11136-009-9487-x DO - 10.1007/s11136-009-9487-x ID - Haugland2009 ER - TY - JOUR AU - Frojd, C. AU - Larsson, G. AU - Lampic, C. AU - Essen, L. PY - 2007 DA - 2007// TI - Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study JO - Health Qual Life Outcomes VL - 5 UR - https://doi.org/10.1186/1477-7525-5-18 DO - 10.1186/1477-7525-5-18 ID - Frojd2007 ER - TY - JOUR AU - Webster, K. O. L. AU - Peterman, A. AU - Lent, L. AU - Cella, D. PY - 1999 DA - 1999// TI - The functional assessment of chronic illness therapy (FACIT) measurement system: validation of version 4 of the core questionnaire JO - Qual Life Res VL - 8 ID - Webster1999 ER - TY - JOUR AU - Jaeschke, R. AU - Singer, J. AU - Guyatt, G. H. PY - 1989 DA - 1989// TI - Measurement of health status. Ascertaining the minimal clinically important difference JO - Control Clin Trials VL - 10 UR - https://doi.org/10.1016/0197-2456(89)90005-6 DO - 10.1016/0197-2456(89)90005-6 ID - Jaeschke1989 ER - TY - JOUR AU - Cella, D. F. AU - Tulsky, D. S. AU - Gray, G. PY - 1993 DA - 1993// TI - The functional assessment of Cancer therapy scale: development and validation of the general measure JO - J Clin Oncol VL - 11 UR - https://doi.org/10.1200/JCO.1993.11.3.570 DO - 10.1200/JCO.1993.11.3.570 ID - Cella1993 ER - TY - JOUR AU - Yost, K. J. AU - Eton, D. T. PY - 2005 DA - 2005// TI - Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience JO - Eval Health Prof VL - 28 UR - https://doi.org/10.1177/0163278705275340 DO - 10.1177/0163278705275340 ID - Yost2005 ER - TY - JOUR AU - Yost, K. J. AU - Eton, D. T. AU - Garcia, S. F. AU - Cella, D. PY - 2011 DA - 2011// TI - Minimally important differences were estimated for six PROMIS-Cancer scales in advanced-stage cancer patients JO - J Clin Epidemiol VL - 64 UR - https://doi.org/10.1016/j.jclinepi.2010.11.018 DO - 10.1016/j.jclinepi.2010.11.018 ID - Yost2011 ER - TY - JOUR AU - Cella, D. AU - Elizabeth, A. H. AU - Kelly, D. PY - 2002 DA - 2002// TI - Meaningful change in Cancer-specific quality of life scores: differences between improvement and worsening JO - Qual Life Res VL - 11 UR - https://doi.org/10.1023/A:1015276414526 DO - 10.1023/A:1015276414526 ID - Cella2002 ER - TY - JOUR AU - Jacobsen, M. B. AU - Hanssen, L. E. PY - 1995 DA - 1995// TI - Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial JO - J Intern Med VL - 237 UR - https://doi.org/10.1111/j.1365-2796.1995.tb01175.x DO - 10.1111/j.1365-2796.1995.tb01175.x ID - Jacobsen1995 ER - TY - JOUR AU - Rinke, A. AU - Muller, H. H. AU - Schade-Brittinger, C. PY - 2009 DA - 2009// TI - Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.22.8510 DO - 10.1200/JCO.2009.22.8510 ID - Rinke2009 ER - TY - JOUR AU - Jimenez-Fonseca, P. AU - Carmona-Bayonas, A. AU - Martin-Perez, E. PY - 2015 DA - 2015// TI - Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors JO - Cancer Metastasis Rev VL - 34 UR - https://doi.org/10.1007/s10555-015-9573-1 DO - 10.1007/s10555-015-9573-1 ID - Jimenez-Fonseca2015 ER - TY - JOUR AU - Arnold, R. AU - Rinke, A. AU - Klose, K. J. PY - 2005 DA - 2005// TI - Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial JO - Clin Gastroenterol Hepatol VL - 3 UR - https://doi.org/10.1016/S1542-3565(05)00481-7 DO - 10.1016/S1542-3565(05)00481-7 ID - Arnold2005 ER - TY - JOUR AU - Pearman, T. P. AU - Beaumont, J. L. AU - Cella, D. AU - Neary, M. P. AU - Yao, J. PY - 2016 DA - 2016// TI - Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden JO - Support Care Cancer VL - 24 UR - https://doi.org/10.1007/s00520-016-3189-z DO - 10.1007/s00520-016-3189-z ID - Pearman2016 ER - TY - JOUR AU - Basch, E. AU - Abernethy, A. P. AU - Mullins, C. D. PY - 2012 DA - 2012// TI - Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2012.42.5967 DO - 10.1200/JCO.2012.42.5967 ID - Basch2012 ER - TY - JOUR AU - Martini, C. AU - Gamper, E. M. AU - Wintner, L. PY - 2016 DA - 2016// TI - Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours JO - Health Qual Life Outcomes VL - 14 UR - https://doi.org/10.1186/s12955-016-0527-2 DO - 10.1186/s12955-016-0527-2 ID - Martini2016 ER - TY - JOUR AU - Chan, D. L. AU - Segelov, E. AU - Singh, S. PY - 2017 DA - 2017// TI - Everolimus in the management of metastatic neuroendocrine tumours JO - Ther Adv Gastroenterol VL - 10 UR - https://doi.org/10.1177/1756283X16674660 DO - 10.1177/1756283X16674660 ID - Chan2017 ER - TY - JOUR AU - Rubin, J. AU - Ajani, J. AU - Schirmer, W. PY - 1999 DA - 1999// TI - Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/JCO.1999.17.2.600 DO - 10.1200/JCO.1999.17.2.600 ID - Rubin1999 ER -